Page 559 - Cardiac Nursing

35
35
q
A
36.
p
A
1 A
1:0
51
1 A
009
t
M
3
3
3
xd
M
xd
1
g
1-5
1-5
g
0/0
0/0
g
51
e 5
p
1:0
e 5
36.
q
q
LWB
LWBK340-c22_
LWB K34 0-c 22_ p pp511-536.qxd 30/06/2009 11:01 AM Page 535 Aptara
K34
1
22_
0-c
6/2
p
t
ara
ara
ara
p
009
6/2
Pa
M
Pa
C HAPTER 2 2 / Acute Coronary Syndromes 535
18. Cannon, C. P., Gibson, C. M., Lambrew, C. T., et al. (2000). Relationship 39. Tillett, W. S., & Garner, R. L. (1933). The fibrinolytic activity of he-
of symptom-onset-to-balloon time and door-to-balloon time with mortal- molytic streptococci. Journal of Experimental Medicine, 58, 485–502.
ity in patients undergoing angioplasty for acute myocardial infarction. 40. Bates, E. R. (2008). Infusion fibrinolytic therapy. In E. R. Bates (Ed.),
JAMA, 283(22), 2941–2947. Reperfusion therapy for acute myocardial infarction (pp. 43–58). New York:
19. De Luca, G., van’t Hof, A. W. J., de Boer, M. J., et al. (2004). Time-to- Informa Heath Care.
treatment significantly affects the extent of ST-segment resolution and my- 41. Bates, E. R. (2005). Fibrinolysis for ST-elevation myocardial infarction:
ocardial blush in patients with acute myocardial infarction treated by pri- First and second generation agents. In E. J. Topol (Ed.), Acute coronary
mary angioplasty. European Heart Journal, 25(12), 1009–1013. syndromes (3rd ed., pp. 199–216). New York: Informa Health Care.
20. Shavelle, D. M., Rasouli, M. L., Frederick, P., et al. (2005). Outcome in 42. The Global Use of Strategies to Open Occluded Coronary Arteries
patients transferred for percutaneous coronary intervention (a national (GUSTO III) Investigators. (1997). A comparison of reteplase with al-
registry of myocardial infarction 2/3/4 analysis). American Journal of Car- teplase for acute myocardial infarction. New England Journal of Medicine,
7
7
6
diology, 96(9), 1227–1232. 337(16), 1118–1123.
6
21. Hochman, J. S., Lamas, G. A., Buller, C. E., et al. (2006). Coronary in- 43. Brener, S. J. (2005). Third-generation fibrinolytic agents and combined fib-
tervention for persistent occlusion after myocardial infarction. New Eng- rinoplatelet lysis for acute myocardial infarction. In E. J. Topol (Ed.), Acute
land Journal of Medicine, 355(23), 2395–2407. coronary syndromes (3rd ed., pp. 217–232). New York: Informa Health Care.
22. DeWood, M. A., Spores, J., Notske, R., et al. (1980). Prevalence of total 44. Bode, C., Smalling, R. W., Berg, G., et al. (1996). Randomized compari-
coronary occlusion during the early hours of transmural myocardial in- son of coronary thrombolysis achieved with double-bolus reteplase (re-
farction. New England Journal of Medicine, 303(16), 897–902. combinant plasminogen activator) and front-loaded, accelerated alteplase
23. Rentrop, K. P., Blanke, H., Karsch, K. R., et al. (1979). Acute myocardial (recombinant tissue plasminogen activator) in patients with acute myocar-
infarction: Intracoronary application of nitroglycerin and streptokinase. dial infarction. The RAPID II Investigators. Circulation, 94(5), 891–898.
Clinical Cardiology, 2(5), 354–363. 45. Van De Werf, F., Adgey, J., Ardissino, D., et al. (1999). Single-bolus
24. Kennedy, J. W., Ritchie, J. L., Davis, K. B., et al. (1983). Western Wash- tenecteplase compared with front-loaded alteplase in acute myocardial in-
ington randomized trial of intracoronary streptokinase in acute myocardial farction: The ASSENT-2 double-blind randomised trial. Lancet,
infarction. New England Journal of Medicine, 309(24), 1477–1482. 354(9180), 716–722.
25. Simoons, M. L., Serruys, P. W., vd Brand, M., et al. (1985). Improved sur- 46. Thompson, P. L., Aylward, P. E., Federman, J., et al. (1991). A random-
vival after early thrombolysis in acute myocardial infarction. A randomised ized comparison of intravenous heparin with oral aspirin and dipyri-
trial by the Interuniversity Cardiology Institute in The Netherlands. damole 24 hours after recombinant tissue-type plasminogen activator for
Lancet, 2(8455), 578–582. acute myocardial infarction. National Heart Foundation of Australia
26. Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico Coronary Thrombolysis Group. Circulation, 83(5), 1534–1542.
(GISSI). (1986). Effectiveness of intravenous thrombolytic treatment in 47. Warkentin, T. E., Levine, M. N., Hirsh, J., et al. (1995). Heparin-induced
acute myocardial infarction. Lancet, 1(8478), 397–402. thrombocytopenia in patients treated with low-molecular-weight heparin
27. Nallamothu, B. K., Bradley, E. H., & Krumholz, H. M. (2007). Time to or unfractionated heparin. New England Journal of Medicine, 332(20),
treatment in primary percutaneous coronary intervention. New England 1330–1335.
Journal of Medicine, 357(16), 1631–1638. 48. Antman, E. M., Morrow, D. A., McCabe, C. H., et al. (2006). Enoxaparin
7
7
28. Thrombolysis in Myocardial Ischemia (TIMI) Investigators. (1994). Ef- versus unfractionated heparin with fibrinolysis for ST-elevation myocardial
fects of tissue plasminogen activator and a comparison of early invasive infarction. New England Journal of Medicine, 354(14), 1477–1488.
and conservative strategies in unstable angina and non-Q-wave myocardial 49. Gibson, C. M., Murphy, S. A., Montalescot, G., et al. (2007). Percuta-
infarction. Results of the TIMI IIIB Trial. Circulation, 89(4), 1545–1556. neous coronary intervention in patients receiving enoxaparin or unfrac-
29. Baigent, C., Collins, R., Appleby, P., et al. (1998). ISIS-2: 10 year survival tionated heparin after fibrinolytic therapy for ST-segment elevation my-
among patients with suspected acute myocardial infarction in randomised ocardial infarction in the ExTRACT-TIMI 25 trial. Journal of American
comparison of intravenous streptokinase, oral aspirin, both, or neither. College of Cardiology, 49(23), 2238–2246.
The ISIS-2 (Second International Study of Infarct Survival) Collaborative 50. Giraldez, R. R., Nicolau, J. C., Corbalan, R., et al. (2007). Enoxaparin is
6
Group. BMJ, 316(7141), 1337–1343. superior to unfractionated heparin in patients with ST elevation myocardial
6
30. Franzosi, M. G., Santoro, E., De Vita, C., et al. (1998). Ten-year follow- infarction undergoing fibrinolysis regardless of the choice of lytic: An Ex-
up of the first megatrial testing thrombolytic therapy in patients with acute TRACT-TIMI 25 analysis. European Heart Journal, 28(13), 1566–1573.
myocardial infarction: Results of the Gruppo Italiano per lo Studio della 51. White, H. D., Braunwald, E., Murphy, S. A., et al. (2007). Enoxaparin vs.
Sopravvivenza nell’Infarto-1 study. The GISSI Investigators. Circulation, unfractionated heparin with fibrinolysis for ST-elevation myocardial in-
98(24), 2659–2665. farction in elderly and younger patients: Results from ExTRACT-TIMI
31. Morrison, L. J., Verbeek, P. R., McDonald, A. C., et al. (2000). Mortality 25. European Heart Journal, 28(9), 1066–1071.
and prehospital thrombolysis for acute myocardial infarction: A meta- 52. Yusuf, S., Mehta, S. R., Chrolavicius, S., et al. (2006). Effects of fonda-
analysis. JAMA, 283(20), 2686–2692. parinux on mortality and reinfarction in patients with acute ST-segment
32. Morrow, D. A., Antman, E. M., Sayah, A., et al. (2002). Evaluation of the elevation myocardial infarction: The OASIS-6 randomized trial. JAMA,
time saved by prehospital initiation of reteplase for ST-elevation myocardial in- 295(13), 1519–1530.
farction: Results of The Early Retavase-Thrombolysis in Myocardial Infarction 53. King, S. B., III, Smith, S. C., Jr., Hirshfeld, J. W., Jr., et al. (2008). 2007
(ER-TIMI) 19 trial. Journal of American College of Cardiology, 40(1), 71–77. focused update of the ACC/AHA/SCAI 2005 guideline update for percu-
33. The European Myocardial Infarction Project Group. (1993). Prehospital taneous coronary intervention: A report of the American College of Car-
thrombolytic therapy in patients with suspected acute myocardial infarc- diology/American Heart Association Task Force on Practice guidelines.
tion. New England Journal of Medicine, 329(6), 383–389. Journal of American College of Cardiology, 51(2), 172–209.
34. Weaver, W. D., Cerqueira, M., Hallstrom, A. P., et al. (1993). Prehospital- 54. Becker, R. C. (2008). Clinical trials of platelet glycoprotein IIb/IIIa receptor
initiated vs hospital-initiated thrombolytic therapy. The Myocardial In- inhibitors in coronary heart disease: Intravenous agents. UpToDate. Retrieved
farction Triage and Intervention Trial. JAMA, 270(10), 1211–1216. August, 2008, http://www.uptodateonline.com/online/content/topic.do?
35. Castaigne, A. D., Herve, C., Duval-Moulin, A. M., et al. (1989). Prehos- topicKey=chd/31791&selectedTitle=6~150&source=search_result.
pital use of APSAC: Results of a placebo-controlled study. American Jour- 55. Brener, S. J., Zeymer, U., Adgey, A. A., et al. (2002). Eptifibatide and low-
nal of Cardiology, 64(2), 30A–33A; discussion 41A–42A. dose tissue plasminogen activator in acute myocardial infarction: The inte-
36. GREAT Group. (1992). Feasibility, safety, and efficacy of domiciliary grilin and low-dose thrombolysis in acute myocardial infarction (INTRO
thrombolysis by general practitioners: Grampian region early anistreplase AMI) trial. Journal of American College of Cardiology, 39(3), 377–386.
trial. BMJ, 305(6853), 548–553. 56. Gold, H. K., Garabedian, H. D., Dinsmore, R. E., et al. (1997). Restora-
37. Roth, A., Barbash, G. I., Hod, H., et al. (1990). Should thrombolytic tion of coronary flow in myocardial infarction by intravenous chimeric
therapy be administered in the mobile intensive care unit in patients with 7E3 antibody without exogenous plasminogen activators. Observations in
evolving myocardial infarction? A pilot study. Journal of American College animals and humans. Circulation, 95(7), 1755–1759.
of Cardiology, 15(5), 932–936. 57. SPEED Investigators. (2000). Trial of abciximab with and without low-
38. Schofer, J., Buttner, J., Geng, G., et al. (1990). Prehospital thrombolysis dose reteplase for acute myocardial infarction. Strategies for Patency En-
in acute myocardial infarction. American Journal of Cardiology, 66(20), hancement in the Emergency Department (SPEED) Group. Circulation,
6
6
1429–1433. 101(24), 2788–2794.